Evolus (EOLS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Evolus (EOLS) is Neutral.

The composite score behind that read is -0.01, weighing +0.00 of bullish evidence against -0.27 bearish.

Evolus last closed at $7.73, -0.90% on the session.

Against the IVW growth benchmark the position is -1.70% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

13 graded predictions for EOLS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Evolus in the 96th percentile on return on equity, where 100 is best.

Evolus is classified under Health Care / Pharmaceuticals, with a market capitalisation of $515.19M.

StockMap tracks Evolus as the 77th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Evolus ranks 59th of 151 in the group, against a group median of -0.08.